AB Science Release: Masitinib is Being Investigated in the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Published: Nov 05, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PARIS, Nov. 4, 2013 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the initiation of a clinical development program with masitinib in the treatment of Amyotrophic Lateral Sclerosis (ALS).

Help employers find you! Check out all the jobs and post your resume.

Back to news